Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer

Federica Tosi, Andrea Sartore-Bianchi, Sara Lonardi, Alessio Amatu, Francesco Leone, Silvia Ghezzi, Cosimo Martino, Katia Bencardino, Erica Bonazzina, Francesca Bergamo, Elisabetta Fenocchio, Erika Martinelli, Teresa Troiani, Giulia Siravegna, Gianluca Mauri, Valter Torri, Giovanna Marrapese, Emanuele Valtorta, Andrea Cassingena, Giovanni CappelloEmanuela Bonoldi, Angelo Vanzulli, Daniele Regge, Fortunato Ciardiello, Vittorina Zagonel, Alberto Bardelli, Livio Trusolino, Silvia Marsoni, Salvatore Siena

Research output: Contribution to journalArticlepeer-review

Abstract

BACKGROUND: ERBB2 amplification occurs in 5% of RAS wild-type metastatic colorectal cancer (mCRC) and it has been shown to be a target for treatment with 2 HER2-directed combinations of trastuzumab and lapatinib or trastuzumab and pertuzumab. We present long-term clinical results of trastuzumab and lapatinib (HERACLES-A trial) at 6.7 years (82 months) follow-up and focus on central nervous system (CNS) recurrences.

PATIENTS AND METHODS: Patients had histologically confirmed KRAS exon 2 (codons 12 and 13) wild-type and HER2-positive mCRC. HER2 positivity was assessed by immunohistochemistry and in situ hybridization HERACLES diagnostic criteria. Patients were treated with intravenous trastuzumab 4 mg/kg loading dose, then 2 mg/kg once per week, and oral lapatinib 1000 mg per day until disease progression or toxicity. Patients who presented with symptoms or signs of CNS disease received brain computed tomography scan or magnetic resonance imaging.

RESULTS: A total of 35 patients received trastuzumab and lapatinib and 32 were evaluable for response. One patient (3%) achieved complete response (CR), 8 (25%) partial response, and 13 (41%) stable disease. Therefore, response rate was 28%. Median progression-free survival was 4.7 months (95% confidence interval [CI] 3.7-6.1). Median overall survival was 10.0 months (95% CI 7.9-15.8). One patient achieved sustained CR still maintained at 7 years of follow-up. Progression in the central nervous system (CNS) occurred in 6 (19%) of 32 patients.

CONCLUSIONS: Long-term (6.7 years) follow-up analysis of HERACLES-A supports using of trastuzumab and lapatinib as treatment reference for KRAS wild-type, chemorefractory HER2-positive mCRC. In this subset of patients, prolongation of survival is accompanied by CNS recurrences that will require diagnostic and therapeutic attention in future studies. Clinicaltrials. Gov identifier: NCT 03225937.

Original languageEnglish
Pages (from-to)256-262.e2
JournalClin. Colorectal Cancer
Volume19
Issue number4
DOIs
Publication statusPublished - Dec 2020

Fingerprint Dive into the research topics of 'Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer'. Together they form a unique fingerprint.

Cite this